Abstract 6068
Background
Photosensitizers (PS) are commonly used in photodynamic therapy to treat skin cancer. PS molecules bind to cell membrane and damage it by singlet oxygen (SO) generated under illumination. In our laboratory, we study in vitro the processes involved in photodynamic therapy on a model bilayer lipid membranes (BLM) by measuring the boundary potential applying the Intramembrane Field Compensation Method (Sokolov and Kuz’min, Biofizika, 25:170, 1980).
Methods
This method allowed to monitor the binding of PS on BLM and damage of target molecules (TM) of SO - di-4-ANEPPS under excitation of PS by light. In present investigation, we studied the adsorption and photodynamic efficiency of new positively charged porphyrins, namely b-imidazolyl substituted porphyrin and it’s Zn(II) and In(III) complexes; and two phosphorus (V) complexes of meso-(p-pyridyl)-triphenylporphyrin bearing hydroxyl and ethoxyl axial ligands. We observed a linear dependence of the boundary potential change on the logarithm of concentrations of each PS.
Results
The photodynamic efficiency of these porphyrins was assessed by determining the rate of oxidation (R) of TM adsorbed either on the same or opposite surface of the BLM where molecules PS were present. The values R for both positions of TM were close indicating that BLM is highly permeable to singlet oxygen. The values R were proportional to surface density of the porphyrin molecules in the membrane.
Conclusions
This investigation indicate that the main factor influencing the photodynamic efficiency of the porphyrins is their adsorption on the BLM. The work was supported by the Russian Foundation for Basic Research (project 19-04-00694) and the Ministry of Education and Science of the Russian Federation in the framework of Increase Competitiveness Program of NUST «MISiS» (№ К4-2017-053).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National University of Science and Technology.
Funding
NUST-MISiS, Russian Science Foundation, Russian Academy of Sciences.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2791 - Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) : a retrospective multicentric study.
Presenter: Geoffroy Bilger
Session: Poster Display session 1
Resources:
Abstract
2916 - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
Presenter: Enrica Capelletto
Session: Poster Display session 1
Resources:
Abstract
1427 - Final results of randomized phase II trial of metronomic vs weekly oral vinorelbine (OV) as first-line chemotherapy (CT) in advanced NSCLC patients unfit to platinum-based CT (P-CT): Tempo-Lung EudraCT Number: 2014-003859-61
Presenter: Dariusz Kowalski
Session: Poster Display session 1
Resources:
Abstract
3789 - Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non–small-cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)
Presenter: Daniel Heudobler
Session: Poster Display session 1
Resources:
Abstract
1519 - Predicting Chemotherapy Toxicity in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Prospective Multicenter Study of the National Hospital Organization in Japan
Presenter: Masaki Kanazu
Session: Poster Display session 1
Resources:
Abstract
1874 - A prospective phase II trial of carboplatin (CBDCA) and nab-paclitaxel (nabPTX) for advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD)
Presenter: Toshiyuki Harada
Session: Poster Display session 1
Resources:
Abstract
3819 - Weekly Epirubicin as palliative treatment in elderly patients with malignant pleural mesothelioma.
Presenter: Paola Candido
Session: Poster Display session 1
Resources:
Abstract
3390 - Survival Prolongation by Rationale INnovative Genomics (SPRING): An international WIN Consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates.
Presenter: Benjamin Solomon
Session: Poster Display session 1
Resources:
Abstract
5069 - Preliminary results from phase 1b study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)
Presenter: Armando Santoro
Session: Poster Display session 1
Resources:
Abstract
2041 - Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC
Presenter: Jose Trigo Perez
Session: Poster Display session 1
Resources:
Abstract